Development of pulmonary tuberculosis following treatment with anti-PD-1 for non-small cell lung cancer

Acta Oncol. 2018 Aug;57(8):1127-1128. doi: 10.1080/0284186X.2018.1433877. Epub 2018 Jan 31.

Authors

Kristian Hastoft Jensen¹, Gitte Persson¹, Anna-Louise Bondgaard², Mette Pøhl¹

Affiliations

¹ a Department of Oncology , Rigshospitalet Copenhagen University Hospital , Copenhagen , Denmark.
² b Department of Pathology , Rigshospitalet Copenhagen University Hospital , Copenhagen , Denmark.

PMID: 29384034
DOI: 10.1080/0284186X.2018.1433877

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antitubercular Agents / therapeutic use
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / immunology
Carcinoma, Non-Small-Cell Lung / pathology
Disease Susceptibility / chemically induced
Disease Susceptibility / immunology
Humans
Immunocompromised Host
Lung Neoplasms / drug therapy*
Lung Neoplasms / immunology
Lung Neoplasms / pathology
Male
Middle Aged
Nivolumab / administration & dosage
Nivolumab / adverse effects*
Programmed Cell Death 1 Receptor / immunology
Tuberculosis, Pulmonary / chemically induced*
Tuberculosis, Pulmonary / drug therapy
Withholding Treatment

Substances

Antitubercular Agents
PDCD1 protein, human
Programmed Cell Death 1 Receptor
Nivolumab